Aligos Therapeutics Inc reports results for the quarter ended in December - Earnings Summary

Aligos Therapeutics

09/03/2023 22:02

* Aligos Therapeutics Inc  ALGS.OQ  reported a quarterly
adjusted
loss of 51 cents​​ per share for the quarter ended in December.
The mean expectation of five analysts for the quarter was for a
loss of 47 cents per share.
    * Revenue rose 863.8% to $3.54 million from a year ago;
analysts
expected $1.72 million. 
    * Aligos Therapeutics Inc's reported EPS for the quarter was
a
loss of 51 cents​.
    * The mean earnings estimate of analysts had risen by
about 3.7%
in the last three months.​ 
    * In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company. 
    * Aligos Therapeutics Inc shares had risen by 52.2% this
quarter.
    * The company reported a quarterly loss of $21.89 million.
    * Wall Street's median 12-month price target for Aligos
Therapeutics Inc is $3.00 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 2 "strong buy" or "buy," 3
"hold" and no "sell" or "strong sell." 

This summary was machine generated from LSEG Refinitiv data
March 9 at 10:01 p.m. UTC. ​All figures in US dollars unless
otherwise stated. QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Dec. 31 2022      -0.47          -0.51          Missed
 Sep. 30 2022      -0.58          -0.44          Beat
 Jun. 30 2022      -0.67          -0.47          Beat
 Mar. 31 2022      -0.73          -0.84          Missed